Home

Staff

Publications

Links

Xia Lab

 

Henrik Zetterberg, M.D., Ph.D.

Research Fellow
Center for Neurologic Diseases
Brigham and Women's Hospital
Harvard Medical School
Harvard Institutes of Medicine, HIM-610
77 Avenue Louis Pasteur
Boston, MA 02115
Tel: 617-525-5780
Fax: 617-525-5305
Email: mailto:henrik.zetterberg@clinchem.gu.se

 

Current Research Interests:

I am studying g-secretase substrates using zebrafish as a model system.

Education

PhD, Goteborg University       2003

License to Practise                  1999

MD, Goteborg University        1998

Professional Training

Postdoctoral Fellow, Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA                            2004-present      

Residency in Clinical Chemistry, Sahlgrenska University Hospital        1999-2004

PhD student, Depterment of Clincal Chemistry and Transfusion, Medicine, Goteborg University                                                                                1999-2004

Internship, Internal Medicine, Surgery, General Practice and Psychiatry, Skaraborg’s Hospital, Skovde, Sweden                                                  1998-1999

Summer Research Assistant, Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital                                             1994-1997

Publications

  1. Zetterberg H, Andreasen N, Blennow K. Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease. Neurosci Lett. 2004 Sep 2;367(2):194-6.
  2. Zetterberg H, Nilsson-Ehle H. False-negative result in the detection of an IgM monoclonal protein by capillary zone electrophoresis. Clin Chem. 2004 Aug 3 [Epub ahead of print].
  3. Zetterberg H, Borestrom C, Nilsson T, Rymo L. Multiple EBNA1-binding sites within oriPI are required for EBNA1-dependent transactivation of the Epstein-Barr virus C promoter. Int J Oncol. 2004 Sep;25(3):693-6.
  4. Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K. APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology. 2004 Jun 8;62(11):2116-8.
  5. Strandhagen E, Zetterberg H, Aires N, Palmer M, Rymo L, Blennow K, Landaas S, Thelle DS. The methylenetetrahydrofolate reductase C677T polymorphism is a major determinant of coffee-induced increase of plasma homocysteine: a randomized placebo controlled study. Int J Mol Med. 2004 Jun;13(6):811-5. 
  6. Zetterberg M, Zetterberg H, Palmer M, Rymo L, Blennow K, Tasa G, Juronen E, Veromann S, Teesalu P, Karlsson JO, Hoglund K. Apolipoprotein E polymorphism in patients with cataract. Br J Ophthalmol. 2004 May;88(5):716-8.
  7. Johansson A, Katzov H, Zetterberg H, Feuk L, Johansson B, Bogdanovic N, Andreasen N, Lenhard B, Brookes AJ, Pedersen NL, Blennow K, Prince JA. Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease. Hum Genet. 2004 May;114(6):581-7.
  8. McCaddon A, Blennow K, Hudson P, Hughes A, Barber J, Gray R, Davies G, Williams JH, Duguid J, Lloyd A, Tandy S, Everall M, Cattell H, McCaddon A, Ellis D, Palmer M, Bogdanovic N, Gottfries CG, Zetterberg H, Rymo L, Regland B. Transcobalamin polymorphism and serum holo-transcobalamin in relation to Alzheimer's disease. Dement Geriatr Cogn Disord. 2004;17(3):215-21.
  9. Zetterberg H, Wahlund LO, Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett. 2003 Nov 27;352(1):67-9.
  10. Zetterberg H, Zafiropoulos A, Spandidos DA, Rymo L, Blennow K. Gene-gene interaction between fetal MTHFR 677C>T and transcobalamin 776C>G polymorphisms in human spontaneous abortion. Hum Reprod. 2003 Sep;18(9):1948-50. 
  11. Zetterberg H, Nexo E, Regland B, Minthon L, Boson R, Palmer M, Rymo L, Blennow K. The transcobalamin (TC) codon 259 genetic polymorphism influences holo-TC concentration in cerebrospinal fluid from patients with Alzheimer disease. Clin Chem. 2003 Jul;49(7):1195-8.
  12. Zetterberg H, Palmer M, Borestrom C, Rymo L, Blennow K. The transcobalamin codon 259 polymorphism should be designated 776C>G, not 775G>C. Blood. 2003 May 1;101(9):3749-50.
  13. Johansson A, Hampel H, Faltraco F, Buerger K, Minthon L, Bogdanovic N, Sjogren M, Zetterberg H, Forsell L, Lilius L, Wahlund LO, Rymo L, Prince JA, Blennow K. Increased frequency of a new polymorphism in the cell division cycle 2 (cdc2) gene in patients with Alzheimer's disease and frontotemporal dementia. Neurosci Lett. 2003 Apr 3;340(1):69-73.
  14. Zetterberg H, Coppola A, D'Angelo A, Palmer M, Rymo L, Blennow K. No association between the MTHFR A1298C and transcobalamin C776G genetic polymorphisms and hyperhomocysteinemia in thrombotic disease. Thromb Res. 2002 Nov 1;108(2-3):127-31.
  15. Borestrom C, Zetterberg H, Liff K, Rymo L. Functional interaction of nuclear factor y and sp1 is required for activation of the epstein-barr virus C promoter. J Virol. 2003 Jan;77(2):821-9.
  16. Zetterberg H, Rymo L, Coppola A, D’Angelo A, Spandidos DA, Blennow K. MTHFR C677T and A1298C polymorphisms and mutated sequences occurring in cis. Eur J Hum Genet. 2003 Jan;11(1):106. 
  17. Zetterberg H, Regland B, Palmer M, Rymo L, Zafiropoulos A, Arvanitis DA, Spandidos DA, Blennow K. The transcobalamin codon 259 polymorphism influences the risk of human spontaneous abortion. Hum Reprod. 2002 Dec;17(12):3033-6.
  18. Zetterberg H, Jansson A, Rymo L, Chen F, Karlsson A, Klein G, Brodin B. The Epstein-Barr virus ZEBRA protein activates transcription from the early lytic F promoter by binding to a promoter-proximal AP-1-like site. J Gen Virol. 2002 Aug;83(Pt 8):2007-14.
  19. Zetterberg H, Palmer M, Ricksten A, Poirier J, Palmqvist L, Rymo L, Zafiropoulos A, Arvanitis DA, Spandidos DA, Blennow K. Influence of the apolipoprotein E epsilon4 allele on human embryonic development. Neurosci Lett. 2002 May 24;324(3):189-92. 
  20. Zetterberg H, Regland B, Palmer M, Ricksten A, Palmqvist L, Rymo L, Arvanitis DA, Spandidos DA, Blennow K. Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos. Eur J Hum Genet. 2002 Feb;10(2):113-8.
  21. Nilsson T, Zetterberg H, Wang YC, Rymo L. Promoter-proximal regulatory elements involved in oriP-EBNA1-independent and -dependent activation of the Epstein-Barr virus C promoter in B-lymphoid cell lines. J Virol. 2001 Jul;75(13):5796-811.
  22. Zetterberg H, Stenglein M, Jansson A, Ricksten A, Rymo L. Relative levels of EBNA1 gene transcripts from the C/W, F and Q promoters in Epstein-Barr virus-transformed lymphoid cells in latent and lytic stages of infection. J Gen Virol. 1999 Feb;80 (Pt 2):457-66.
  23. Campbell WA, Yang H, Zetterberg H, Baulac S, Sears JA, Liu T, Wong STC, Zhong TP, Xia W.  Zebrafish lacking Alzheimer presenilin enhancer 2 (Pen-2) demonstrate excessive p53 dependent apoptosis and neuronal loss.  J Neurochem. 2006, 96, 1423-40.
  24. Zetterberg H, Campbell WA, Yang HW, Xia W. The cytosolic loop of the gamma-secretase component presenilin enhancer 2 (Pen-2) protects zebrafish embryos from apoptosis.  J Biol Chem. 2006, in press.

Reviews

  1. Zetterberg H. Methylenetetrahydrofolate reductase and transcobalamin genetic polymorphisms in human spontaneous abortion: biological and clinical implications. Reprod Biol Endocrinol. 2004 Feb 17;2(1):7. 
  2. Zetterberg H, Blennow K, Xia W.  RNA interference: applications in research on amyloidogenesis in Alzheimer's disease.  Progress in RNA Res. 2004, in press.
  3. Zetterberg, H, Blennow K. Cerebrospinal fluid markers for early and accurate diagnosis of Alzheimer's disease. Revue de Neuropsychologie, 2004.
  4. Zetterberg H. Epstein-Barr virus nukleära antigen 1 och konsten att gömma sig i immunförsvaret. Medikament. 2004;9(3):34-8.